文献速递胸部肿瘤放疗放疗物理与技术

利用手术数据构建的影像组学模型预测立体定向体部放疗治疗的临床I期非小细胞肺癌区域复发与预后

Predicting Regional Recurrence and Prognosis in Stereotactic Body Radiation Therapy-Treated Clinical Stage I Non-small Cell Lung Cancer Using a Radiomics Model Constructed With Surgical Data.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-06-25

本研究利用2013年至2020年接受根治性手术及系统淋巴结清扫的临床I期非小细胞肺癌患者数据构建预测隐匿性淋巴结转移的影像组学模型,并在2个学术医疗中心连续接受SBRT治疗的早期NSCLC患者队列中验证其预测区域复发的价值。影像组学模型在训练集和验证集的AUC分别为0.85和0.83,加入临床特征未提升性能。SBRT队列中位随访40.0个月,213例中32例发生区域复发,高风险组累积区域复发率更高且区域无复发生存、无进展生存和总生存更短。

要点

  • 基于术前CT的影像组学模型预测隐匿性淋巴结转移,训练集AUC 0.85,验证集AUC 0.83。
  • SBRT队列213例中32例发生区域复发,影像组学高风险组累积区域复发率更高(P < .001)。
  • 高风险组区域无复发生存(P = .02)、无进展生存(P = .004)和总生存(P = .006)均较低风险组更短。

核心结论

  • 基于病理确诊数据构建的影像组学模型能有效识别隐匿性淋巴结转移,可能有助于SBRT治疗的临床I期NSCLC患者风险分层。

研究设计与样本

  • 利用2013年1月至2018年12月(训练队列)和2019年1月至2020年12月(验证队列)接受根治性手术及系统淋巴结清扫的临床I期NSCLC患者数据,构建预测隐匿性淋巴结转移的术前CT影像组学模型、临床特征模型和融合模型。
  • 将影像组学模型应用于2个学术医疗中心连续接受SBRT治疗的早期NSCLC患者队列,预测区域复发。

主要发现

  • 共纳入769例患者,影像组学模型包含8个CT特征,训练队列AUC为0.85(95% CI,0.81-0.89),验证队列AUC为0.83(95% CI,0.80-0.88)。
  • 加入临床特征未改善影像组学模型的性能。
  • SBRT队列中位随访40.0个月(95% CI,35.2-44.8),213例中32例发生区域复发。
  • 影像组学高风险组较低风险组累积区域复发率更高(P < .001),区域无复发生存(P = .02)、无进展生存(P = .004)和总生存(P = .006)更短。

关键数值与推荐

  • 影像组学模型预测隐匿性淋巴结转移的训练队列AUC为0.85(95% CI,0.81-0.89),验证队列AUC为0.83(95% CI,0.80-0.88)。
  • SBRT队列中位随访40.0个月(95% CI,35.2-44.8),213例中32例发生区域复发。
  • 影像组学高风险组较低风险组累积区域复发率更高(P < .001)。
  • 影像组学高风险组较低风险组区域无复发生存更短(P = .02)。
  • 影像组学高风险组较低风险组无进展生存更短(P = .004),总生存更短(P = .006)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Risk stratification of regional recurrence (RR) is clinically important in the design of adjuvant treatment and surveillance strategies in patients with clinical stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). This study aimed to develop a radiomics model predicting occult lymph node metastasis (OLNM) using surgical data and apply it to the prediction of RR in SBRT-treated early-stage NSCLC patients. METHODS AND MATERIALS: Patients with clinical stage I NSCLC who underwent curative surgery with systematic lymph node dissection from January 2013 to December 2018 (the training cohort) and from January 2019 to December 2020 (the validation cohort) were included. A preoperative computed tomography-based radiomics model, a clinical feature model, and a fusion model predicting OLNM were constructed. The performance of the 3 models was quantified and compared in the training and validation cohorts. Subsequently, the radiomics model was used to predict RR in a cohort of consecutive SBRT-treated early-stage NSCLC patients from 2 academic medical centers. RESULTS: A total of 769 patients were included. Eight computed tomography features were identified in the radiomics model, achieving areas under the curves of 0.85 (95% CI, 0.81-0.89) and 0.83 (95% CI, 0.80-0.88) in the training and validation cohorts, respectively. Nevertheless, adding clinical features did not improve the performance of the radiomics model. With a median follow-up of 40.0 (95% CI, 35.2-44.8) months, 32 of the 213 patients in the SBRT cohort developed RR and those in the high-risk group based on the radiomics model had a higher cumulative incidence of RR (P < .001) and shorter regional recurrence-free survival (P = .02), progression-free survival (P = .004) and overall survival (P = .006) than those in the low-risk group. CONCLUSIONS: The radiomics model based on pathologically confirmed data effectively identified patients with OLNM, which may be useful in the risk stratification among SBRT-treated patients with clinical stage I NSCLC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ni J, Chen H, Yu L, et al. Predicting Regional Recurrence and Prognosis in Stereotactic Body Radiation Therapy-Treated Clinical Stage I Non-small Cell Lung Cancer Using a Radiomics Model Constructed With Surgical Data. Int J Radiat Oncol Biol Phys. 2024. PMID: 38936632. doi:10.1016/j.ijrobp.2024.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。